Syndax Pharmaceuticals Inc - Understand $sndx stock

$SNDX Market Cap: $1.532 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$3.500M

TTM

Gross Margin

Net Earnings

-$264.1M

TTM

Current Assets

$446.1M

Q2 2024

Current Liabilities

$42.47M

Q2 2024

Current Ratio

1050.24%

Q2 2024

Total Assets

$476.9M

Q2 2024

Total Liabilities

$42.61M

Q2 2024

Book Value

$434.3M

Q2 2024

Cash

$105.4M

Q2 2024

P/E

-5.800

Sep 18, 2024 EST

Free Cash Flow

-$41.35M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$0.00	$0.00	$139.7M	$1.520M	$1.517M	$1.520M	$2.108M	$1.220M	$627.0K	$0.00	$0.00	$0.00	$0.00
YoY Change		-100.0%	9091.38%	0.2%	-0.2%	-27.89%	72.79%	94.58%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Revenue	$0.00	$0.00	$139.7M	$1.520M	$1.517M	$1.520M	$2.108M	$1.220M	$627.0K	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Selling, General & Admin	$66.92M	$33.26M	$25.24M	$22.51M	$16.06M	$17.29M	$15.86M	$13.32M	$11.59M	$11.16M	$5.360M	$3.490M	$3.540M
YoY Change	101.22%	31.76%	12.13%	40.16%	-7.11%	9.02%	19.07%	14.93%	3.85%	108.21%	53.58%	-1.41%
% of Gross Profit
Research & Development	$163.0M	$118.5M	$88.25M	$50.44M	$42.99M	$60.11M	$48.20M	$31.67M	$9.549M	$10.18M	$3.210M	$5.340M	$6.090M
YoY Change	37.58%	34.28%	74.96%	17.33%	-28.48%	24.71%	52.22%	231.61%	-6.15%	216.98%	-39.89%	-12.32%
% of Gross Profit
Depreciation & Amortization	$12.00M	$33.00M	$43.00K	$90.00K	$90.00K	$78.00K	$76.00K	$89.00K	$21.00K	$15.00K	$10.00K	$30.00K	$50.00K
YoY Change	-63.64%	76644.19%	-52.22%	0.0%	15.38%	2.63%	-14.61%	323.81%	40.0%	50.0%	-66.67%	-40.0%
% of Gross Profit
Operating Expenses	$230.0M	$151.8M	$113.5M	$72.94M	$59.06M	$77.39M	$64.06M	$44.99M	$21.14M	$21.33M	$8.570M	$8.830M	$9.620M
YoY Change	51.53%	33.72%	55.59%	23.51%	-23.69%	20.81%	42.4%	112.8%	-0.9%	148.91%	-2.94%	-8.21%
Operating Profit	-$230.0M	-$151.8M	$26.22M	-$71.42M	-$57.54M	-$75.88M	-$61.95M	-$43.77M	-$20.51M	-$21.33M
YoY Change	51.53%	-678.78%	-136.71%	24.13%	-24.17%	22.47%	41.56%	113.36%	-3.84%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Interest Expense	$208.0K	$3.137M	$1.899M	$2.357M	$1.570M	$1.940M	$1.421M	$956.0K	-$1.414M	-$289.0K	-$770.0K	-$1.470M	-$1.990M
YoY Change	-93.37%	65.19%	-19.43%	50.13%	-19.07%	36.52%	48.64%	-167.61%	389.27%	-62.47%	-47.62%	-26.13%
% of Operating Profit			7.24%
Other Income/Expense, Net	$20.59M	$2.419M	-$1.294M	-$1.735M	$1.492M	$1.915M	$1.152M	-$706.0K	-$3.606M	$1.504M	-$4.830M	$380.0K	-$1.480M
YoY Change	751.34%	-286.94%	-25.42%	-216.29%	-22.09%	66.23%	-263.17%	-80.42%	-339.76%	-131.14%	-1371.05%	-125.68%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Pretax Income	-$209.4M	-$149.3M	$24.93M	-$73.16M	-$56.05M	-$73.96M	-$60.80M	-$44.47M	-$24.12M	-$19.83M	-$14.17M	-$9.920M	-$13.09M
YoY Change	40.19%	-699.13%	-134.07%	30.53%	-24.22%	21.64%	36.72%	84.37%	21.63%	39.94%	42.84%	-24.22%
Income Tax			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00		$0.00	$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$209.4M	-$149.3M	$24.93M	-$73.16M	-$56.05M	-$73.96M	-$60.80M	-$44.47M	-$24.12M	-$19.83M	-$14.17M	-$9.920M	-$13.09M
YoY Change	40.19%	-699.13%	-134.07%	30.53%	-24.22%	21.64%	36.72%	84.39%	21.64%	39.93%	42.84%	-24.22%
Net Earnings / Revenue			17.84%	-4813.03%	-3694.59%	-4865.86%	-2884.35%	-3645.25%	-3846.73%
Basic Earnings Per Share	-$2.98	-$2.46	$0.48	-$1.87	-$1.84
Diluted Earnings Per Share	-$2.98	-$2.46	$0.46	-$1.87	-$1.84	-$2.915M	-$2.895M	-$3.042M	-$1.389M	-$1.142M	-$815.8K	-$571.1K	-$753.6K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Cash & Short-Term Investments	$577.6M	$484.4M	$446.8M	$297.7M	$61.10M	$81.60M	$131.3M	$107.0M	$87.30M	$12.20M	$14.30M	$600.0K	$4.200M
YoY Change	19.24%	8.41%	50.09%	387.23%	-25.12%	-37.85%	22.71%	22.57%	615.57%	-14.69%	2283.33%	-85.71%
Cash & Equivalents	$295.4M	$74.36M	$222.0M	$115.2M	$24.60M	$33.80M	$35.20M	$23.80M	$23.20M	$10.00M	$10.10M	$500.0K	$3.600M
Short-Term Investments	$282.2M	$410.0M	$224.9M	$182.5M	$36.50M	$47.80M	$96.10M	$83.10M	$64.10M	$2.200M	$4.200M	$100.0K	$600.0K
Other Short-Term Assets	$2.066M	$1.332M	$1.137M	$900.0K	$1.200M	$1.500M	$1.800M	$1.200M	$800.0K	$300.0K	$300.0K	$100.0K	$200.0K
YoY Change	55.11%	17.15%	26.33%	-25.0%	-20.0%	-16.67%	50.0%	50.0%	166.67%	0.0%	200.0%	-50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$580.9M	$489.8M	$448.4M	$298.9M	$62.30M	$83.30M	$133.4M	$108.5M	$88.00M	$12.40M	$14.50M	$700.0K	$4.400M
YoY Change	18.6%	9.23%	50.02%	379.78%	-25.21%	-37.56%	22.95%	23.3%	609.68%	-14.48%	1971.43%	-84.09%
Property, Plant & Equipment	$1.495M	$1.059M	$1.261M	$500.0K	$1.000M	$400.0K	$300.0K	$300.0K	$100.0K	$0.00	$0.00	$0.00	$100.0K
YoY Change	41.17%	-16.02%	152.2%	-50.0%	150.0%	33.33%	0.0%	200.0%				-100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$29.83M	$5.469M				$0.00	$3.200M
YoY Change	445.42%					-100.0%
Other Assets	$680.0K	$922.0K	$0.00	$1.300M	$200.0K	$200.0K	$200.0K	$200.0K	$1.800M	$300.0K	$2.500M	$800.0K	$300.0K
YoY Change	-26.25%		-100.0%	550.0%	0.0%	0.0%	0.0%	-88.89%	500.0%	-88.0%	212.5%	166.67%
Total Long-Term Assets	$32.00M	$7.450M	$1.261M	$1.700M	$1.200M	$600.0K	$3.800M	$500.0K	$1.900M	$400.0K	$2.600M	$800.0K	$400.0K
YoY Change	329.58%	490.8%	-25.82%	41.67%	100.0%	-84.21%	660.0%	-73.68%	375.0%	-84.62%	225.0%	100.0%
Total Assets	$612.9M	$497.2M	$449.7M	$300.6M	$63.50M	$83.90M	$137.2M	$109.0M	$89.90M	$12.80M	$17.10M	$1.500M	$4.800M
YoY Change
Accounts Payable	$9.961M	$4.350M	$5.669M	$3.500M	$6.200M	$1.400M	$2.200M	$2.400M	$1.500M	$400.0K	$1.100M	$800.0K	$800.0K
YoY Change	128.99%	-23.27%	61.97%	-43.55%	342.86%	-36.36%	-8.33%	60.0%	275.0%	-63.64%	37.5%	0.0%
Accrued Expenses	$40.89M	$24.71M	$14.83M	$11.60M	$10.70M	$13.10M	$12.00M	$6.800M	$2.200M	$3.500M	$1.700M	$2.700M	$1.900M
YoY Change	65.48%	66.66%	27.82%	8.41%	-18.32%	9.17%	76.47%	209.09%	-37.14%	105.88%	-37.04%	42.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$12.00K	$5.000K	$0.00	$2.300M					$0.00	$6.400M	$0.00	$21.30M	$7.800M
YoY Change	140.0%		-100.0%						-100.0%		-100.0%	173.08%
Total Short-Term Liabilities	$58.10M	$29.07M	$20.68M	$18.90M	$18.40M	$16.10M	$15.80M	$10.40M	$4.800M	$10.30M	$2.700M	$25.10M	$13.40M
YoY Change	99.88%	40.53%	9.43%	2.72%	14.29%	1.9%	51.92%	116.67%	-53.4%	281.48%	-89.24%	87.31%
Long-Term Debt	$10.00K	$13.00K	$19.90M	$17.80M	$0.00	$0.00	$0.00	$0.00	$0.00	$7.400M	$0.00	$0.00	$6.200M
YoY Change	-23.08%	-99.93%	11.77%						-100.0%			-100.0%
Other Long-Term Liabilities	$578.0K	$709.0K	$711.0K	$11.70M	$13.60M	$14.80M	$17.10M	$14.50M	$18.40M	$800.0K	$2.500M	$5.100M	$4.300M
YoY Change	-18.48%	-0.28%	-93.92%	-13.97%	-8.11%	-13.45%	17.93%	-21.2%	2200.0%	-68.0%	-50.98%	18.6%
Total Long-Term Liabilities	$588.0K	$722.0K	$20.61M	$29.50M	$13.60M	$14.80M	$17.10M	$14.50M	$18.40M	$8.200M	$2.500M	$5.100M	$10.50M
YoY Change	-18.56%	-96.5%	-30.15%	116.91%	-8.11%	-13.45%	17.93%	-21.2%	124.39%	228.0%	-50.98%	-51.43%
Total Liabilities	$58.68M	$29.79M	$41.29M	$48.40M	$31.90M	$30.90M	$32.90M	$24.90M	$23.20M	$18.50M	$5.200M	$30.20M	$23.80M
YoY Change	97.01%	-27.86%	-14.69%	51.72%	3.24%	-6.08%	32.13%	7.33%	25.41%	255.77%	-82.78%	26.89%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	70.37M	60.76M	52.07M	41.31M	30.49M
Diluted Shares Outstanding	70.37M	60.76M	53.62M	41.31M	30.49M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $1.5317 Billion

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. The company is headquartered in Waltham, Massachusetts and currently employs 112 full-time employees. The company went IPO on 2016-03-03. The company is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. The company is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. The company is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. The company is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Industry: Pharmaceutical Preparations Peers: Akero Therapeutics Inc Celldex Therapeutics Inc BridgeBio Pharma Inc Veracyte Inc Catalyst Pharmaceuticals Inc Day One Biopharmaceuticals Inc Dynavax Technologies Corp Ligand Pharmaceuticals Inc Vaxcyte Inc